The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.

Key information relevant to the recruitment process for the
overall study, such as dates of the recruitment period and locations

No text entered.

Pre-Assignment Details

Significant events and approaches for the overall study
following participant enrollment, but prior to group assignment

No text entered.

Reporting Groups

Description

Effect on Latent HIV of Adding Raltegravir and VPA to ART

Single arm pilot study that measured the effect of adding Raltegravir and Valproic acid (VPA) and current antiretroviral therapy (ART) on the persistence of latent HIV infection within circulating, resting CD4+ T cells in patients stably suppressed by ART

Explanation of how the number of participants for analysis was determined.
Includes whether analysis was per protocol, intention to treat, or another method.
Also provides relevant details such as imputation technique, as appropriate.

No text entered.

Reporting Groups

Description

Effect on Latent HIV of Adding Raltegravir and/or VPA to ART

Single arm pilot study that measured the effect of adding Raltegravir and/or VPA and current ART on the persistence of latent HIV infection within circulating, resting CD4+ T cells in patients stably suppressed by ART

Baseline Measures

Effect on Latent HIV of Adding Raltegravir and/or VPA to ART

Overall Participants Analyzed [Units: Participants]

6

Age [Units: Participants]

<=18 years

0

Between 18 and 65 years

6

>=65 years

0

Age [Units: Years]Mean (Standard Deviation)

36 (8)

Gender [Units: Participants]

Female

0

Male

6

Region of Enrollment [Units: Participants]

United States

6

Outcome Measures

1. Primary:

A Change in the Number of HIV Infected Cells. [ Time Frame: 20 weeks ]

Single arm pilot study that measured the effect of adding Raltegravir and/or VPA and current ART on the persistence of latent HIV infection within circulating, resting CD4+ T cells in patients stably suppressed by ART